An Overview of NecroSearch International

Manage webcast
Dr. Thomas R. Bellinger, President of NecroSearch International
This presentation will provide an introduction to NecroSearch International, a non-profit, multi-disciplinary organization dedicated to the location of clandestine graves and evidence. A brief history of NecroSearch will be presented along with a description of the organization's mission (research, training, and investigation) and case acceptance protocol. Several of the organization's expertise categories will be discussed along with a description of NecroSearch's investigative process. The presentation will conclude with a case example.
Apr 9 2009
44 mins
An Overview of NecroSearch International
More from this community:

Forensic Science

  • Live and recorded (243)
  • Upcoming (3)
  • Date
  • Rating
  • Views
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Computer Aided Synthetic Design: How ARChem Can Improve Your Efficiency and Creativity

    Are you looking for a better way to synthesize a target molecule?

    Have you hit a roadblock in the lab or need an extra burst of creative thinking?

    Join Orr Ravitz at 10:00 AM (EDT) on July 16th for an overview of the future of synthetic design and the software that can help improve your efficiency and creativity in the lab with ARChem.

    He will discuss how medicinal chemists, process chemists and material scientists use ARChem as an idea generator – a tool for route scouting, for brain storming sessions, for the daily synthesis planning and potentially provide an alternative that gets you to curated experimental pathways faster than exploring the literature.

    This webinar will cover:

    ◦The technology behind ARChem and real life case studies
    ◦How ARChem can improve your productivity and creativity in the lab
    ◦Future developments of our synthetic design software
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information about how patients, physicians and payers behave through the use of open source, social media and real world data. However, segmentation still lacks clear insight into why these stakeholders behave as they do – and therefore how best to change their behaviour.
    Working with behavioural change experts Hamell, this one hour live discussion will look at why current segmentation strategies are failing, and the importance of understanding what drives patient or customer behaviour. Using case studies, speakers will explore how segmenting by behavioural drivers can create advanced, effective strategies to change patient, customer and payer behaviour.
    This event will focus on three key areas:

    •The theory behind behavioural segmentation and how it challenges the status quo
    •Benefits of behavioural segmentation communication strategies and the problems answered by behavioural segmentation strategies
    •Behavioural segmentation in action: practical application of this approach
  • Life sciences companies need to make better use of the insights that real world data (RWD) can provide in order to improve market access, sales and market growth strategies – and ultimately to improve the applicability of new and existing therapeutics for patients. Insights come not just from the multiple sources of RWD available, but from advanced analytics that highlight the effectiveness of a treatment by geographic area, and link healthcare providers, institutions and patients to relevant and meaningful outcomes.

    This one-hour event will take a hands-on approach – detailing how insights derived from RWD (and collaboratively with other sources) are enabling all elements of the life science industry to do things better.

    Insights experts Robin Munro and Christian Marcazzo will deliver case studies on how RWD can help life science companies in:

    Sales and Marketing – incorporate RWD and evidence into segmentation, targeting, and engagement of physicians and institutions
    Commercial Effectiveness – measure commercial campaigns, and demonstrate the impact to the healthcare system
    Medical Affairs – find and engage medical education prospects and target appropriate healthcare authorities, healthcare professionals and payers, to improve quality of care and outcomes
    Public Affairs and Market Access – develop qualitative and quantitative insights to design education, advocacy and access-related campaigns within the healthcare ecosystem

    The event will also give an exclusive look at what can be achieved from combining data sources – using Diabetes in England as a case study, Zephyr has implemented novel methods to demonstrate an evidence-based approach to improving information sharing within sales teams and to engaging accounts and payers. We explore how patient outcomes from RWD can add value to commercial strategy.
  • Cell lines remain the workhorses of laboratory research, both in academic and industrial settings. This webinar will focus on best practice in selecting and maintaining cell lines for research, to ensure research outputs are relevant and reproducible. Features of cell lines that might be used in selection will be discussed. This will include monolayer or suspension culture; passage number; doubling time; immortalisation; karyotype; receptors; expression profiling and use of bioinformatics tools like the cancer cell line encyclopaedia. Using breast cancer as an exemplar, I will discuss more specifically how to choose the most relevant cell line model to address a particular research question. Finally I will describe how to use (and access) human material to help develop more clinically relevant cell culture systems to model human disease and the role that biobanks play in this process.
  • Cell lines remain the workhorses of laboratory research, both in academic and industrial settings. This webinar will focus on best practice in selecting and maintaining cell lines for research, to ensure research outputs are relevant and reproducible. Features of cell lines that might be used in selection will be discussed. This will include monolayer or suspension culture; passage number; doubling time; immortalisation; karyotype; receptors; expression profiling and use of bioinformatics tools like the cancer cell line encyclopaedia. Using breast cancer as an exemplar, I will discuss more specifically how to choose the most relevant cell line model to address a particular research question. Finally I will describe how to use (and access) human material to help develop more clinically relevant cell culture systems to model human disease and the role that biobanks play in this process.
  • The way that physicians want and need to consume information is changing, almost to the point of being unrecognisable from the tried and tested methods of yesteryear, Working in conjunction with Ashfield Healthcare this event brings together Medical Futurist Dr Bertalan Meskó, Dr Partha Kar, Consultant Endocrinologist, Portsmouth Hospitals NHS Trust, with Ruth Herman and Nigel Campbell of Ashfield, which recently launched the Medical Education Future Forum and will be presenting insights from this unique programme.

    Taking place on the 21st May at 12.30 (UK), 13.30 (EU), 07.30 (E. US) and moderated by pharmaphorum's CEO Paul Tunnah, the debate will centre on three key questions,

    Why and how are physicians changing the way they receive information?
    What are the trends and technologies shaping the landscape of medical communication?
    What are the implications of this for pharma (with examples)?
  • Improve Your Mass Spectrometry Workflows With the New NIST Software, Featuring the Wiley 10th/NIST 2014

    Hosted by Prof David Sparkman

    Release 2.2 is one of the most significant improvements in NIST’s MS Search software. Prof Sparkman will lead an online webinar providing insight into the latest improvements in the most popular mass spectrometry program on the planet, with insights into how you can improve and speed up your analyses by using the full suite of functions available in MS Search 2.2 and the power of using these with the broadest compound coverage available.
    -Compatibility and systems interface tips
    -Retention time workflow
    -LCMSn workflow
    -Accurate mass workflow
    -Search strategies
    -Compound coverage strategies
  • Regardless of the colour of the next UK government that emerges as a result of the May election, the £30-£50bn NHS budget chasm is the abyss that all the parties fear in respect of its thereat to quality health service delivery and re-election.

    With political backs to the abyss, no hostages will be taken. It is not unrealistic to expect a well co-ordinated and concerted offence by politicians and patient organisations alike on industry pricing of innovative speciality and rare diseases medicines:

    With this scenario in mind pharmaphorum is once again working with IMS Health to bring you expert insight into what this means for the UK health system and more specifically market access for specialist treatments in the post-election environment.

    Angela McFarlane, Senior principal IMS Health Local Market Access, Anthony Grosso, Principal Pharmacist at the National Hospital for Neurology and Neurosurgery and Sheela Upadhyaya, previously a NHS Senior Manager with over 17 years of experience in the delivery of services and in commissioning of highly specialised services for rare and ultra rare conditions, combine with pharmaphorum's Paul Tunnah to deliver an accurate analysis and frontline insight as to the already complex roadmap for access is about to change again.

    This one hour event will include analysis of informed predictions which include:

    The NICE HTA criteria will get tougher post end to end review (IMMTreV)
    NICE and the NHS England will join forces to streamline access pre/post NICE
    Risk at local level will be shifted to Providers under the new marginal tariff arrangements; which could indeed see a close to the CDF as the PbR excluded drugs list becomes a thing of a glorious past
    Provider baselines will take the strain of innovation - the tough decisions will be softened by a drive to really accelerate uptake of NICE approved medicines

    How can industry prepare for these changes in what is already a tough and complex environment?
  • Channel
  • Channel profile
  • Body Fluid Identification by RNA Expression Profiling Recorded: Oct 7 2009 49 mins
    Jack Ballantyne, Assoc Director; National Center For Forensic Science
    The serology-based methods routinely used in forensic casework for the identification of biological fluids have varying and often limited degrees of sensitivity and specificity. A novel strategy for the identification of the body fluid origin of dried forensic biological material (blood, semen, saliva, vaginal secretions and menstrual blood) involves expression profiling of body fluid specific messenger and small RNAs (mRNA and miRNA). RNA analysis may permit not only a molecular-based approach with a greater specificity than that of conventional methodologies for the identification of forensically relevant biological fluids, but may also provide strategies particularly suited for the analysis of environmentally impacted or degraded samples frequently encountered in forensic casework. This presentation will describe highly specific RNA methods for body fluid identification that exhibit promise for forensic casework analysis.
  • Forensic DNA: STR, MiniSTR, Y-STR or mtDNA? Recorded: Sep 10 2009 49 mins
    Amarjit Chahal, Senior Director; Warnex Pro-DNA Services, Inc.
    The analysis of regular STR DNA has become the “gold standard” of identification in forensic casework. There are numerous cases though where biological evidence exists but regular DNA testing can’t provide probative evidence or insufficient nuclear DNA was obtained. This presentation will describe casework scenarios where miniSTR, Y-STR and/or mtDNA can provide probative evidence.
  • The 2009 Report on Forensic Sciences from the National Academies Recorded: Apr 9 2009 49 mins
    Brian Zubel: Attorney at Law and Forensic Science Legal Consultant
    In February 2009, the National Research Council of the National Academies released its report entitled Strengthening Forensic Science in the United States: A Path Forward. The substantive findings underscore that many traditional forensic disciplines are in scientific crisis, having never been the subject of rigorous validation. This presentation outlines the major findings of the Report, and the impact it will have on the roles of prosecutors, defense attorneys and judges in the rapidly evolving scientific/legal landscape.
  • The National Clearinghouse for Science, Technology & the Law Recorded: Apr 9 2009 39 mins
    Diana Botluk; Director of Research at NCSTL at Stetson Uni. College of Law
    This program will explore information and research resources in forensic science, focusing primarily on the resources available from the National Clearinghouse for Science, Technology and the Law at Stetson University College of Law. It will demonstrate features of ncstl.org, such as the free research database, Cold Case Toolkit, Education Center, and other online resources designed to keep you updated with the latest scientific evidence information.
  • An Overview of NecroSearch International Recorded: Apr 9 2009 44 mins
    Dr. Thomas R. Bellinger, President of NecroSearch International
    This presentation will provide an introduction to NecroSearch International, a non-profit, multi-disciplinary organization dedicated to the location of clandestine graves and evidence. A brief history of NecroSearch will be presented along with a description of the organization's mission (research, training, and investigation) and case acceptance protocol. Several of the organization's expertise categories will be discussed along with a description of NecroSearch's investigative process. The presentation will conclude with a case example.
  • Generic Microfluidic Platform for Ultrafast Forensic DNA Analysis Recorded: Jan 30 2009 49 mins
    James Landers, University of Virginia, Professor Chemistry
    Generic Microfluidic Platform for Ultrafast Forensic DNA Analysis
  • Y-STR and Forensic Identification Recorded: Jan 27 2009 46 mins
    Amarjit Chahal, Laboratory Director & General Manager at Molecular World Inc
    Part of the nuclear DNA that is paternally inherited or passed down from father to son is found on the Y chromosome. Similar to mitochondrial DNA, Y-chromosome testing can be used to distinguish between individuals with different paternal lineages. Short tandem repeats (STR) on Y chromosome are called Y-STRs. Y-STR testing is identical to analyses of nuclear autosomal STR loci. Testing for this type of DNA is particularly useful when mixtures of male DNA (a minor male contributor) and female DNA (predominant female contributor) are suspected or only distant paternal relatives are available for comparisons. The presentation will introduce audience to Y-STR testing with a particular focus on the probative value of Y-STR DNA test reports.
  • DNA in the Courtroom - Current Issues Recorded: Jan 27 2009 45 mins
    Brian Zubel: Attorney at Law and Forensic Science Legal Consultant
    The presentation will begin with a discussion of the effective presentation of DNA evidence in court, including admissibility standards, foundational issues and the limits of argument. Current-generation legal and scientific challenges to DNA will be explored through the review of several recent cases.
  • Lifting latent fingerprints off textured surfaces Recorded: Jan 27 2009 42 mins
    Dick Warrington: Crime Scene instructor/Consultant,Lynn Peavey Company
    This presentation will show the attendees three methods of lifting developed latent fingerprints off textured surfaces. The three methods that we will talk about are Diff-Lift tape, Mikrosil, and AccuTrans. By using one of these methods demonstrated you’ll be able to lift processed latent fingerprints off a car dash, refrigerators, bank countertops, computers, house siding and a golf ball, just to name a few.
  • Estimation of the Time of Deposition of Bloodstains Recorded: Jan 27 2009 48 mins
    Jack Ballantyne, Assoc Director (Research);National Center For Forensic Science
    The development of powerful and robust DNA typing strategies has made it is possible to ascertain with a high degree of certainty whether a biological stain found at a crime scene originated from a particular individual. However, the possibility of obtaining additional information from biological stains exists. For example, the ability to determine the relative time since deposition (TSD) of biological stains could provide law enforcement investigators with novel probative evidence by establishing an approximation of the time of commission of criminal offenses. However, no reliable TSD methods are available at present. We have developed a novel strategy for the determination of the time since deposition of dried bloodstains using spectrophotometric analysis of hemoglobin. An examination of the Soret band in aged bloodstains has revealed a previously unidentified hypsochromic shift (shift to shorter wavelength). The extent of this shift permits a distinction to be made between stains that were deposited minutes, hours, days and months prior to analysis. The effects of temperature and humidity have also been evaluated.
  • Digital Forensics Private Investigation Laws Recorded: Dec 4 2008 41 mins
    Dave Kleiman- Independent Computer Forensic Consultant
    Digital Forensics and the PI Laws: What is happening, and what you can do to help!
  • Trace Evidence for the Forensic Investigator Recorded: Dec 4 2008 60 mins
    M. Dawn Watkins & King C. Brown of the Palm Beach Police Departments
    Collection and Preservation of Trace Evidence at the Crime Scene and in the Lab.
  • How to Improve Forensic Science Recorded: Dec 4 2008 49 mins
    Roger Koppl, Director of the Institute for Forensic Science Administration
    The current institutional structure of police forensics gives each lab a monopoly in the analysis of the police evidence it receives.
    Forensic scientists have inadequate incentives to produce reliable analyses of police evidence. We should have "competitive self regulation" for police forensics. Each jurisdiction would have several competing forensic labs. Sometimes, evidence would be divided and sent to three separate labs. Chance would determine which labs would receive evidence to analyze. Competitive self regulation improves forensics by creating incentives for error prevention, detection and correction. Surprisingly, it would also reduce the costs of running the criminal justice system.
  • Mitochondrial DNA and Forensic Identification Recorded: Dec 4 2008 58 mins
    Amarjit Chahal, Laboratory Director & Technical Leader, Molecular World Inc
    Mitochondrial DNA and Forensic Identification
  • Domain Irrelevant Information as an Infectious Disease Recorded: Dec 4 2008 23 mins
    D. Michael Risinger, John J. Gibbons Professor of Law, Seton Hall University
    Domain Irrelevant Information as an Infectious Disease in Forensic Science Practice

    In this presentation, Professor Risinger discusses the distorting effects of case information irrelevant to the exercise of one's expertise on the results interpretive processes in forensic science, analogizing such information to an infectious disease. The empirical record bearing on these issues is examined, particularly those empirical results specifically relevant to forensic science practice.
  • DNA and the Duke Lacrosse Case - The Blue Devils in the Details Recorded: Dec 4 2008 39 mins
    Diane MB Savage, Attorney at Law
    This presentation helps lawyers view complex DNA cases in a new light, while comparing the Duke Lacrosse Case to others. Attorneys do not have to concede when they hear the words "match" or "defendant cannot be excluded". Instead, they should remember that besides standing for deoxyribonucleic acid, DNA also stands for DO NOT ACCEPT at face value. This article looks at the DNA evidence in the Duke Lacrosse case and compares the evidence in that case with DNA evidence in other cases.

    This presentation offers practical tips on reviewing complex data generated in DNA cases, discusses the importance of the proper collection and preservation of DNA evidence, discusses the likelihood and ways DNA evidence is subject to contamination, and outlines specific ways to cross-examine DNA experts.
  • Low copy number (LCN) DNA profiling Recorded: Oct 14 2008 46 mins
    Dan Krane, Professor, Wright State University
    PCR-based DNA tests have greatly improve the capabilities of forensic laboratories. The great successes of these tests have inevitably led to efforts to characterize smaller and smaller amounts of material. As the quantity of DNA template associated with a DNA profile test decreases, the likelihood that the results of the test will be compromised by stochastic effects increases. Questions about the significance of results in such circumstances will be addressed
    -- particularly as they pertain to a prominent acquittal in the United Kingdom where low copy number test results played a central role in the prosecution's case.
  • Ultra-Violet & Infrared Capture of Crime Scene Evidence Recorded: Sep 30 2008 45 mins
    King Brown and M. Dawn Watkins of the Palm Beach Police Department
    The IR-UV camera is a new breakthrough in the forensic field that allows us to drop the background color say a black shirt and show the blood stain patterns, thus allowing for photography, collection testing interpretation of the pattern.
  • Increasing probative value of degraded or limited DNA evidence Recorded: Sep 30 2008 33 mins
    Dr. Amarjit Chahal, Laboratory Director & Technical Leader, Molecular World Inc
    Increasing the probative value of degraded or limited DNA evidence by combining two or more DNA technologies: Combining DNA data from all technologies (for example partial nuclear DNA profile, Y-STR profile and mitochondrial DNA profile in case of degraded samples) to increase the probative value of final DNA test report.
  • Bayesian Bias in Forensic Science Recorded: Sep 30 2008 31 mins
    Roger Koppl, Institute for Forensic Science Administration Fairleigh Dickinson
    The organization of forensic science creates inappropriate biases that will sometimes skew results from the truth. These biases exist even when forensic scientists are perfectly rational and untouched by the sort of psychological infirmities some researchers have emphasized.
    Because perfectly rational actors are Bayesian updaters, we may use the term "Bayesian bias" to identify this organizational problem in forensics.
bridging the gap between science and law
Featuring some of the leading thinkers in forensic science today, this channel will provide you with timely knowledge in your field.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: An Overview of NecroSearch International
  • Live at: Apr 9 2009 2:00 pm
  • Presented by: Dr. Thomas R. Bellinger, President of NecroSearch International
  • From:
Your email has been sent.
or close
You must be logged in to email this